Yu Nathan Y, Sio Terence T, Ernani Vinicius, Savvides Panayiotis, Schild Steven E
Department of Radiation Oncology, and.
Division of Hematology and Medical Oncology, Mayo Clinic Hospital, Phoenix, Arizona.
J Natl Compr Canc Netw. 2021 Dec;19(12):1465-1469. doi: 10.6004/jnccn.2021.7105.
Patients with small cell lung cancer (SCLC) are at significant risk of developing brain metastases during their disease course. Prophylactic cranial irradiation (PCI) has been incorporated into SCLC treatment guidelines to diminish the risk of developing brain metastases. In 2007, a randomized trial suggested that PCI decreases the incidence of brain metastases and prolongs overall survival (OS) in patients with extensive-stage SCLC (ES-SCLC) who have responded to initial therapy. However, this study did not include modern central nervous system imaging with CT or MRI prior to randomization. A more recent Japanese trial with MRI staging and surveillance demonstrated that PCI diminished the incidence of brain metastases but did not improve survival. This review examines the largest clinical studies, controversies, and future directions of PCI in patients with ES-SCLC.
小细胞肺癌(SCLC)患者在其病程中发生脑转移的风险很高。预防性颅脑照射(PCI)已被纳入SCLC治疗指南,以降低发生脑转移的风险。2007年,一项随机试验表明,PCI可降低广泛期小细胞肺癌(ES-SCLC)患者在初始治疗有反应后的脑转移发生率,并延长总生存期(OS)。然而,这项研究在随机分组前未包括采用CT或MRI的现代中枢神经系统成像检查。最近一项采用MRI分期和监测的日本试验表明,PCI可降低脑转移发生率,但并未改善生存率。本综述探讨了ES-SCLC患者PCI的最大规模临床研究、争议点及未来方向。